Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM)

• Published in: Scientific reports Vol. 9; no. 1; pp. 10173 - 8
• Main Authors: Ferguson, Robert, Archambault, Alexi, Simpson, Danny, Morales, Leah, Chat, Vylyny, Kazlow, Esther, Lax, Rebecca, Yoon, Garrett, Moran, Una, Shapiro, Richard, Pavlick, Anna, Polsky, David, Osman, Iman, Kirchhoff, Tomas
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 15-07-2019; Nature Publishing Group
• Subjects: 45; 45/22; 45/56; 45/77; 631/67/1813/1634; 631/67/68; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Genetic diversity; Genetic variance; Genotyping; Germ Cells - physiology; Germ-Line Mutation - genetics; Health risks; Humanities and Social Sciences; Humans; Immune system; Immunomodulation; Immunomodulation - genetics; Male; Melanoma; Melanoma - genetics; Middle Aged; Mortality risk; multidisciplinary; Neoplasms, Multiple Primary - genetics; Neoplasms, Multiple Primary - mortality; Risk Factors; Risk reduction; Science; Science (multidisciplinary); Skin Neoplasms - genetics; Survival
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-019-46665-z

Multiple primary melanoma (MPM) has been associated with a higher 10-year mortality risk compared to patients with single primary melanoma (SPM). Given that 3–8% of patients with SPM develop additional primary melanomas, new markers predictive of MPM risk are needed. Based on the evidence that the immune system may regulate melanoma progression, we explored whether germline genetic variants controlling the expression of 41 immunomodulatory genes modulate the risk of MPM compared to patients with SPM or healthy controls. By genotyping these 41 variants in 977 melanoma patients, we found that rs2071304, linked to the expression of
SPI1
, was strongly associated with MPM risk reduction (OR = 0.60; 95% CI = 0.45–0.81; p = 0.0007) when compared to patients with SPM. Furthermore, we showed that rs6695772, a variant affecting expression of BATF3, is also associated with MPM-specific survival (HR = 3.42; 95% CI = 1.57–7.42; p = 0.0019). These findings provide evidence that the genetic variation in immunomodulatory pathways may contribute to the development of secondary primary melanomas and also associates with MPM survival. The study suggests that inherited host immunity may play an important role in MPM development.